Understanding Glycosylation Inhibitors in Disease Pathways
As glycobiology continues to expand its impact on biomedical science, the role of enzyme inhibitors—especially those targeting glycan-related pathways—is becomi...
ginghamjudd
.
CD BioGlyco Launches GalNAc-L96 Platform for Targeted siRNA Delivery to Hep...
CD BioGlyco has rolled out a newly designed nucleic acid drug delivery system for siRNA- and mRNA-based therapeutics.